Imaging genomics of glioblastoma: Biology, biomarkers, and breakthroughs

Topics in Magnetic Resonance Imaging

Volumn 24, Issue 3, 2015, Pages 155-163

  Moton, Safwan ^a   Elbanan, Mohamed ^a   Zinn, Pascal O ^b   Colen, Rivka R ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

biomarkers; glioma; IDH1; imaging genomics; MGMT; radiogenomics; radiophenotypes

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOGLUTARIC ACID; APOLIPOPROTEIN E; BEVACIZUMAB; BIOLOGICAL MARKER; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; MICRORNA 219; ONCOLYTIC VIRUS; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG; TUMOR MARKER;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CONTRAST ENHANCEMENT; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENOMICS; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; IMAGING; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; BRAIN NEOPLASMS; PATHOLOGY; PROCEDURES;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; GENOMICS; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 84931833137     PISSN: 08993459     EISSN: 15361004     Source Type: Journal    
DOI: 10.1097/RMR.0000000000000052     Document Type: Review

References (103)

1. National Expenditures for Cancer Care. Cancer Prevalence and Cost of Care Projections. 2010. Available at: http://costprojections.cancer.gov/expenditures.html. Accessed March 5, 2014.
2. American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society Inc; 2011.
3. Ostrom QT, Gittleman H, Liao P, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 (suppl 4): iv1-iv63.
4. Stupp R, Hegi ME, Mason WP, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-466.
5. Zinn PO, Sathyan P, Mahajan B, A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. PLoS One. 2012; 7: e41522.
6. Larjavaara S, Mantyla R, Salminen T, Incidence of gliomas by anatomic location. Neuro Oncol. 2007; 9: 319-325.
7. Kyritsis AP, Bondy ML, Rao JS, Inherited predisposition to glioma. Neuro Oncol. 2010; 12: 104-113.
8. Farr LE, Sweet WH, Robertson JS, Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am J Roentgenol Radium Ther Nucl Med. 1954; 71: 279-293.
9. Van Meir EG, Hadjipanayis CG, Norden AD, Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010; 60: 166-193.
10. Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
11. Minniti G, Muni R, Lanzetta G, Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009; 29: 5171-5184.
12. Chinot OL, Wick W, Mason W, Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370: 709-722.
13. Gilbert MR, Dignam JJ, Armstrong TS, A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370: 699-708.
14. Gliadel wafers for treatment of brain tumors. Med Lett Drugs Ther. 1998; 40: 92.
15. Colen RR, Zinn PO, Hazany S, Magnetic resonance imaging appearance and changes on intracavitary Gliadel wafer placement: a pilot study. World J Radiol. 2011; 3: 266-272.
16. Verhaak RG, Hoadley KA, Purdom E, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17: 98-110.
17. Longo DL,. Tumor heterogeneity and personalized medicine. N Engl J Med. 2012; 366: 956-957.
18. Lang FF, Conrad C, Gomez-Manzano C, First-in-human phase I clinical trial of oncolytic Delta-24-RGD (DNX-2401) with biological endpoints: implications for viro-immunotherapy. Neuro Oncol. 2014; 16 (suppl 3): iii39.
19. Jaffe CC,. Imaging and genomics: is there a synergy? Radiology. 2012; 264: 329-331.
20. Nagarajan RP, Costello JF,. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol. 2009; 19: 188-197.
21. Stricker SH, Feber A, Engstrom PG, Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev. 2013; 27: 654-669.
22. Clarke J, Penas C, Pastori C, Epigenetic pathways and glioblastoma treatment. Epigenetics. 2013; 8: 785-795.
23. Alizadeh AA, Staudt LM,. Genomic-scale gene expression profiling of normal and malignant immune cells. Curr Opin Immunol. 2000; 12: 219-225.
24. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455: 1061-1068.
25. Parsons DW, Jones S, Zhang X, An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-1812.
26. Zinn PO, Colen RR,. Imaging genomic mapping in glioblastoma. Neurosurgery. 2013; 60 (suppl 1): 126-130.
27. Simon R,. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med. 2010; 7: 33-47.
28. Pegg AE,. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res. 2000; 462: 83-100.
29. Esteller M, Garcia-Foncillas J, Andion E, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343: 1350-1354.
30. Weller M, Stupp R, Reifenberger G, MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010; 6: 39-51.
31. Colman H, Aldape K,. Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol. 2008; 65: 877-883.
32. Hegi ME, Diserens AC, Godard S, Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004; 10: 1871-1874.
33. Hegi ME, Diserens AC, Gorlia T, MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003.
34. Kato T, Natsume A, Toda H, Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 2010; 17: 1363-1371.
35. Frezza C, Tennant DA, Gottlieb E,. IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell. 2010; 17: 7-9.
36. Yan H, Parsons DW, Jin G, IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-773.
37. Dang L, White DW, Gross S, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462: 739-U752.
38. Zhao S, Lin Y, Xu W, Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009; 324: 261-265.
39. Sanson M, Marie Y, Paris S, Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27: 4150-4154.
40. von Deimling A, Korshunov A, Hartmann C,. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 2011; 21: 74-87.
41. van den Bent MJ, Dubbink HJ, Marie Y, IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010; 16: 1597-1604.
42. SongTao Q, Lei Y, Si G, IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012; 103: 269-273.
43. Walker C, Baborie A, Crooks D, Biology, genetic and imaging of glial cell tumours. Br J Radiol. 2011; 84 (spec iss 2): S090-S106.
44. Ohgaki H,. Genetic pathways to glioblastomas. Neuropathology. 2005; 25: 1-7.
45. Fan QW, Cheng CK, Gustafson WC, EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 2013; 24: 438-449.
46. Zadeh G, Bhat KP, Aldape K,. EGFR and EGFRvIII in glioblastoma: partners in crime. Cancer Cell. 2013; 24: 403-404.
47. Barker FG 2nd, Simmons ML, Chang SM, EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001; 51: 410-418.
48. Heimberger AB, Hlatky R, Suki D, Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005; 11: 1462-1466.
49. Mellinghoff IK, Wang MY, Vivanco I, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005; 353: 2012-2024.
50. Wachsberger PR, Lawrence RY, Liu Y, Epidermal growth factor receptor (EGFR) mutation status and Rad51 determine the response of glioblastoma (GBM) to multimodality therapy with cetuximab, temozolomide and radiation. Front Oncol. 2013; 3: 13.
51. Yang RY, Yang KS, Pike LJ, Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors. Chem Biol Drug Des. 2010; 76: 1-9.
52. Godoy PR, Mello SS, Magalhaes DA, Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines. Mutat Res. 2013; 756: 46-55.
53. Ohgaki H, Kleihues P,. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013; 19: 764-772.
54. Phillips HS, Kharbanda S, Chen R, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9: 157-173.
55. Gutman DA, Cooper LA, Hwang SN, MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology. 2013; 267: 560-569.
56. Feng Y, Wang Z, Bao Z, SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients. PLoS One. 2014; 9: e91829.
57. Noushmehr H, Weisenberger DJ, Diefes K, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17: 510-522.
58. Al-Okaili RN, Krejza J, Wang S, Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics. 2006; 26 (suppl 1): S173-S189.
59. Osborn AG, Salzman KL, Barkovich AJ,. Diagnostic Imaging: Brain, Second Edition. Amirsys, Utah. 2010; 4: 18-21.
60. Le Bihan D, Douek P, Argyropoulou M, Diffusion and perfusion magnetic resonance imaging in brain tumors. Top Magn Reson Imaging. 1993; 5: 25-31.
61. Zulfiqar M, Yousem DM, Lai H,. ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor? A meta-analysis. AJR Am J Roentgenol. 2013; 200: 624-629.
62. Ferre JC, Shiroishi MS, Law M,. Advanced techniques using contrast media in neuroimaging. Magn Reson Imaging Clin N Am. 2012; 20: 699-713.
63. Barajas RF, Chang JS, Segal MR, Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2009; 253: 486-496.
64. Law M, Yang S, Wang H, Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003; 24: 1989-1998.
65. Jain R, Poisson L, Narang J, Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology. 2013; 267: 212-220.
66. Sorensen AG, Emblem KE, Polaskova P, Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012; 72: 402-407.
67. Bisdas S, Kirkpatrick M, Giglio P, Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? Am J Neuroradiol. 2009; 30: 681-688.
68. Cho YD, Choi GH, Lee SP, (1)H-MRS metabolic patterns for distinguishing between meningiomas and other brain tumors. Magn Reson Imaging. 2003; 21: 663-672.
69. Kassner A, Thornhill RE,. Texture analysis: a review of neurologic MR imaging applications. AJNR Am J Neuroradiol. 2010; 31: 809-816.
70. Chaddad A, Zinn PO, Colen RR,. Quantitative texture analysis for glioblastoma phenotypes discrimination. Paper presented at the 2nd International Conference on Control, Decision and Information Technologies (CoDIT); November 3-5, 2014; Metz, France.
71. Rutman AM, Kuo MD,. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol. 2009; 70: 232-241.
72. ElBanan MG, Amer AM, Zinn PO, Imaging genomics of Glioblastoma: state of the art bridge between genomics and neuroradiology. Neuroimaging Clin N Am. 2015; 25: 141-153.
73. Barajas RF Jr, Hodgson JG, Chang JS, Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology. 2010; 254: 564-576.
74. Bookheimer SY, Strojwas MH, Cohen MS, Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000; 343: 450-456.
75. Diehn M, Nardini C, Wang DS, Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci USA. 2008; 105: 5213-5218.
76. Aghi M, Gaviani P, Henson JW, Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res. 2005; 11 (24 pt 1): 8600-8605.
77. Drabycz S, Roldan G, de Robles P, An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 2010; 49: 1398-1405.
78. Pope WB, Chen JH, Dong J, Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 2008; 249: 268-277.
79. Mut M, Turba UC, Botella AC, Neuroimaging characteristics in subgroup of GBMs with p53 overexpression. J Neuroimaging. 2007; 17: 168-174.
80. 6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res. 2007; 13: 2606-2613.
81. Moon WJ, Choi JW, Roh HG, Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology. 2012; 54: 555-563.
82. Zlatescu MC, TehraniYazdi A, Sasaki H, Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001; 61: 6713-6715.
83. 6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage. 2012; 59: 908-916.
84. Ellingson BM, Lai A, Harris RJ, Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol. 2013; 34: 533-540.
85. Carrillo JA, Lai A, Nghiemphu PL, Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012; 33: 1349-1355.
86. Zhang T, Wang Y, Fan X, Anatomical localization of p53 mutated tumors: a radiographic study of human glioblastomas. J Neurol Sci. 2014; 346: 94-98.
87. Zinn PO, Mahajan B, Sathyan P, Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One. 2011; 6: e25451.
88. Naeini KM, Pope WB, Cloughesy TF, Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol. 2013; 15: 626-634.
89. Colen RR, Wang J, Singh SK, Glioblastoma: imaging genomic mapping reveals sex-specific oncogenic associations of cell death. Radiology. 2015; 275: 215-227.
90. Barajas RF, Phillips JJ, Parvataneni R, Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol. 2012; 14: 942-954.
91. Nguyen ML, Willows B, Khan R, The potential role of magnetic resonance spectroscopy in image-guided radiotherapy. Front Oncol. 2014; 4: 91.
92. Pope WB, Mirsadraei L, Lai A, Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. AJNR Am J Neuroradiol. 2012; 33: 1059-1064.
93. Colen R, Jaafrani R, Zinn P,. Diffusion imaging genomic mapping identifies genomic targets involved in invasion and poor prognosis. Paper presented at the Annual Meeting of the Society of Neuro-Oncology; November 21-24, 2013; San Francisco, California.
94. Gupta A, Young RJ, Shah AD, Pretreatment dynamic susceptibility contrast MRI perfusion in glioblastoma: prediction of EGFR gene amplification. Clin Neuroradiol. 2014: 1-8.
95. Maia AC Jr, Malheiros SM, da Rocha AJ, MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol. 2005; 26: 777-783.
96. Colen R, TCGA Phenotype Group, Zinn P,. Perfusion imaging genomic mapping uncovers potential genomic targets involved in angiogenesis and invasion. Annual Meeting of the Society of Neuro-Oncology; November 21-24, 2013; San Francisco, California.
97. Andronesi OC, Rapalino O, Gerstner E, Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest. 2013; 123: 3659-3663.
98. Pope WB, Prins RM, Thomas MA, Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012; 107: 197-205.
99. Choi C, Ganji SK, DeBerardinis RJ, 2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012; 18: 624-629.
100. Kalinina J, Carroll A, Wang L, Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. J Mol Med (Berlin, Germany). 2012; 90: 1161-1171.
101. Levner I, Drabycz S, Roldan G, Predicting MGMT methylation status of glioblastomas from MRI texture. Med Image Comput Comput Assist Interv. 2009; 12 (pt 2): 522-530.
102. Arvinda HR, Kesavadas C, Sarma PS, Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol. 2009; 94: 87-96.
103. Pope WB,. Genomics of brain tumor imaging. Neuroimaging Clin N Am. 2015; 25: 105-119.